Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer

  • Authors:
    • Yoshihito Yokoyama
    • Masayuki Futagami
    • Jun Watanabe
    • Naoki Sato
    • Yukihiro Terada
    • Fumiharu Miura
    • Toru Sugiyama
    • Tadao Takano
    • Nobuo Yaegashi
    • Takanobu Kojimahara
    • Hirohisa Kurachi
    • Hiroshi Nishiyama
    • Keiya Fujimori
    • Toru Tase
    • Hideki Mizunuma
  • View Affiliations

  • Published online on: December 10, 2013     https://doi.org/10.3892/mco.2013.223
  • Pages: 212-218
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment‑free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III̸IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first‑line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression‑free survival (PFS) following the second‑line treatment. in patients with serous̸endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell̸mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell̸mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous̸endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell̸mucinous adenocarcinoma who relapsed within 12 months as platinum‑resistant and those who relapsed after 12 months as platinum‑sensitive.
View Figures
View References

Related Articles

Journal Cover

March 2014
Volume 2 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yokoyama, Y., Futagami, M., Watanabe, J., Sato, N., Terada, Y., Miura, F. ... Mizunuma, H. (2014). Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Molecular and Clinical Oncology, 2, 212-218. https://doi.org/10.3892/mco.2013.223
MLA
Yokoyama, Y., Futagami, M., Watanabe, J., Sato, N., Terada, Y., Miura, F., Sugiyama, T., Takano, T., Yaegashi, N., Kojimahara, T., Kurachi, H., Nishiyama, H., Fujimori, K., Tase, T., Mizunuma, H."Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer". Molecular and Clinical Oncology 2.2 (2014): 212-218.
Chicago
Yokoyama, Y., Futagami, M., Watanabe, J., Sato, N., Terada, Y., Miura, F., Sugiyama, T., Takano, T., Yaegashi, N., Kojimahara, T., Kurachi, H., Nishiyama, H., Fujimori, K., Tase, T., Mizunuma, H."Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer". Molecular and Clinical Oncology 2, no. 2 (2014): 212-218. https://doi.org/10.3892/mco.2013.223